Evidence map›Paper›PMID 42151851›Full record

ArticleBMC pregnancy and childbirth2026

Chronic liver disease questionnaire analysis in pregnant women with hepatitis B: a prospective study.

Yueying Deng, Weizhen Chen, Ying Lin, Tingting Peng, Dan Xie, Ziren Chen, Shi OuYang

Abstract read
In one paragraph

Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yueying Deng *Department of Infectious Diseases, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital ofGuangzhou Medical University, No. 621, Gangwan Road, Huangpu District, Guangzhou, 510799, China.
Weizhen Chen *Department of Infectious Diseases, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital ofGuangzhou Medical University, No. 621, Gangwan Road, Huangpu District, Guangzhou, 510799, China.
Ying Lin *Department of Infectious Diseases, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital ofGuangzhou Medical University, No. 621, Gangwan Road, Huangpu District, Guangzhou, 510799, China.
Tingting PengDepartment of Infectious Diseases, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital ofGuangzhou Medical University, No. 621, Gangwan Road, Huangpu District, Guangzhou, 510799, China.
Dan XieDepartment of Infectious Diseases, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital ofGuangzhou Medical University, No. 621, Gangwan Road, Huangpu District, Guangzhou, 510799, China.
Ziren ChenDepartment of Infectious Diseases, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital ofGuangzhou Medical University, No. 621, Gangwan Road, Huangpu District, Guangzhou, 510799, China.
Shi OuYangDepartment of Infectious Diseases, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital ofGuangzhou Medical University, No. 621, Gangwan Road, Huangpu District, Guangzhou, 510799, China. ouyangshi@gzhmu.edu.cn.ORCID http://orcid.org/0000-0003-0173-3276

Funding

2022 Guangzhou Medical University discipline construction projects 02-410-22060132022 Student Innovation Capacity Enhancement Program Project of Guangzhou Medical University 02-408-2304-19064XM2023 City school (college) enterprise joint funding projects 2023A03J04212024 Tertiary Education Scientific research project of Guangzhou Municipal Education Bureau 2024312257Construction and Application Research of a Clinical Monitoring and Early Warning System for the COVID-19 Pandemic 2023YFC3043500Guangdong Basic and Applied Research Foundation 2023A1515220242Guangzhou Medical University First-Class Discipline Construction Project - 2025 College Student Innovation Training Program 02-408-2501-2214Key Laboratory of Guangdong Higher Education Institutes 2021KSYS009Plan on enhancing scientific research in GMU 02-410-2302092XM
6 · The paper itself

Abstract

backgroundAlthough domestic and international guidelines increasingly emphasize preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV), the multidimensional impacts of HBV infection on pregnant women's health-related quality of life (HRQoL) have received insufficient attention. Our previous 1:1 matched cohort study [1] identified HBV infection as an independent risk factor for impaired HRQoL in pregnant women, after adjusting for age, gestational age, and parity. Building upon this foundation, this study is a longitudinal descriptive investigation within the population of HBV-infected pregnant women, aiming to delineate HRQoL trajectories and identify stage-specific factors.

methodsThis study enrolled 126 pregnant women with hepatitis B who attended the Fifth Affiliated Hospital of Guangzhou Medical University between April 2023 and May 2024. The participants were followed up at three time points: 16-24 weeks of gestation, 32 weeks of gestation to delivery, and 5-13 weeks postpartum. The Chronic Liver Disease Questionnaire (CLDQ) was used for longitudinal assessment of changes in their HRQoL. Repeated-measures analysis of variance (RMANOVA) was applied to examine the trends of CLDQ scores, while one-way analysis of variance and multiple linear regression were used to identify influencing factors.

resultsHRQoL in HBV-infected pregnant women showed significant dynamic changes over time (total score time effect: F = 28.363, P < 0.001), with the emotional function and fatigue domains most severely impaired during late pregnancy. In mid-pregnancy, a supportive family environment was positively associated with improved systemic symptoms and emotional function (β = 0.206, P = 0.029; β = 0.366, P = 0.001), whereas out-of-pocket medical expenditures were linked to exacerbated fatigue (β =-0.444, P = 0.044). In late pregnancy, out-of-pocket payments (β =-0.680, P = 0.022) and older age (β =-0.055, P = 0.027) were associated with reduced vitality. During the postpartum period, clinical markers of HBV infection, specifically high viral load (β =-0.403, P = 0.020) and HBeAg positivity (β =-0.336, P = 0.026), correlated with worsened abdominal symptoms and fatigue, respectively. Furthermore, women receiving antiviral therapy for the prevention of mother-to-child transmission demonstrated lower scores in the vitality and emotional function domains (all P < 0.01).

conclusionsHRQoL trajectories in HBV-infected pregnant women exhibit pronounced stage-specific variations, with notable declines in physiological and emotional function during late pregnancy. Different factors influence HRQoL at each stage, suggesting that clinical management should adopt targeted interventions tailored to each phase. Enhanced symptom monitoring and psychological support during late pregnancy and the postpartum period should be prioritized.

Indexed as

Hepatitis BHepatitis B, ChronicPregnancy Complications, InfectiousQuality of LifeAdultChinaFemaleHumansInfectious Disease Transmission, VerticalLongitudinal StudiesPregnancyProspective StudiesSurveys and QuestionnairesChronic hepatitis BCLDQHealth-related quality of lifePregnancyRisk factors

Identifiers

PMID42151851
PMCPMC13348562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.